AbbVie has announced a collaboration with Voyager Therapeutics to develop tau-targeted vectorised antibodies for the treatment of Alzheimer’s disease (AD) and potentially other neurodegenerative diseases. The aim of the option-based alliance is to develop a one-time treatment using Voyager’s gene therapy platform to reduce tau build-up, which is thought to lead to impaired brain function. The AD therapy area has been plagued by development setbacks and there is a tremendous need for new therapies in this area.